ImuLyme vaccine based on the OspA outer surface lipoprotein of the Lyme disease spirochete data

Phase III testing has shown reduced incidence of the disease, according to preliminary

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE